The sea of ​​stars, set sail - the 2022 edition of the "CSCO Prostate Cancer Diagnosis and Treatment Guidelines" update officially launched!

*Only for medical professionals to read and refer to the 2022 edition of the "CSCO Prostate Cancer Diagnosis and Treatment Guidelines" update work officially kicked off! Let us look forward to the next "Guide Update Hotspot Analysis Meeting" to bring more exciting! In order to continuously improve the concept of standardized diagnosis and treatment of prostate cancer in China and improve the survival outcomes of prostate cancer patients in China, Professor Ye Dingwei, the head of the writing group of the CSCO (Chinese Society of Clinical Oncology) Prostate Cancer Expert Committee, Professor Guo Jun, Professor He Zhisong, Under the call and organization of Professor Qi Jun, Professor Shi Benkang, Professor Wei Qiang, Professor Xie Xiaodong and Professor Zhou Fangjian, Secretary and writing expert Professor Zhu Yao, as well as writing experts Professor Sheng Xinan, Professor Fan Yu, Professor Liu Hailong, Professor Chen Shouzhen, Professor Zeng Hao , Prof.
Guo Fang, Prof.
Li Yonghong, Prof.
He Liru and Prof.
Gu Weijie, combined with domestic and foreign evidence-based medical evidence, tailored for the Chinese population and successively released the 2020 and 2021 editions of the "CSCO Prostate Cancer Diagnosis and Treatment Guidelines"
.

Once the guideline was released, it was widely welcomed by clinical medical staff, and many lecture tours were organized all over the country, which became an important and authoritative reference material for the majority of urological medical staff in clinical work
.

The spring is coming, and Vientiane is updated.
This guideline keeps pace with the times.
Organized by the CSCO Prostate Cancer Special Committee, the 2022 edition of the "CSCO Prostate Cancer Guideline" launch update meeting was successfully held today, and the update of the 2022 edition of the guideline was officially started! At the beginning of the meeting, Professor Ye Dingwei, chairman of the CSCO Prostate Cancer Special Committee and leader of the CSCO Prostate Cancer Diagnosis and Treatment Guidelines Writing Group, delivered a wonderful speech, pointing out that the previously released 2020 and 2021 editions of the "CSCO Prostate Cancer Diagnosis and Treatment Guidelines" have been well received by the majority of prostate cancer patients.
A warm welcome from experts and scholars in the field of cancer
.

With the continuous improvement and development of the diagnosis and treatment of prostate cancer at home and abroad, the clinical experience based on evidence-based medicine has been continuously promoted.
The update work of the 2022 edition will continue to follow the core spirit of the CSCO guidelines, and adhere to the principle of "based on an international perspective, focusing on Chinese characteristics; Focusing on specific subtypes, paying equal attention to precision and standardization; combining treatment to increase efficiency, combination is better than sequential" concept, this update work is more open and inclusive.
It is worth mentioning that after the official launch meeting, domestic experts will also be organized to conduct " "Guideline Update Hotspot Analysis Series", fully discussing the latest progress in the diagnosis and treatment of prostate cancer at home and abroad, laying the foundation and leading the way for this year's guideline update work, and finally creating the most suitable guideline for Chinese prostate cancer patients! Professor Guo Jun, Professor He Zhisong, Professor Qi Jun, Professor Shi Benkang, Professor Wei Qiang, Professor Xie Xiaodong and Professor Zhou Fangjian sent comments on the guidelines and affirmed the "CSCO Prostate Cancer Guidelines".
"The advantages and value of pocket books in clinical practice, I look forward to this update work to continue to introduce more high-quality evidence-based medical evidence, especially research on the Chinese population, to maximize the use of the guideline in clinical practice in China.
value! At this kick-off meeting, Dean Ye specially commended and thanked the gold medal speakers of the "2021 CSCO Guidelines for the Diagnosis and Treatment of Prostate Cancer".
With their professional knowledge and superb speaking skills, the speakers made a detailed interpretation of the guidelines.
Contributed a lot to the application and promotion of the guide! Professor Zhu Yao from Fudan University Affiliated Cancer Hospital shared the update plan and academic hotspot analysis of the CSCO prostate cancer diagnosis and treatment guidelines
.

In particular, the updated characteristics of this guideline are pointed out: based on an international perspective and focusing on Chinese characteristics, it is proposed that Chinese scholars represented by Professor Ye Dingwei of Fudan University Cancer Hospital participated in the compilation of international guidelines and consensus (APCCC, ESMO Asia) for the first time, and Chinese prostate cancer patients The main research has entered the international stage
.

Focus on specific subtypes, precise specification and emphasize three "importances": pay attention to the treatment of intraductal carcinoma and neuroendocrine differentiated carcinoma with poor prognosis; pay attention to standardized detection and treatment of patients with HRR mutations; pay attention to prostate-specific membrane antigen (PSMA) Diagnostic and therapeutic value in prostate cancer
.

Combination therapy is more effective than sequential.
It is pointed out that a new era of "triple therapy" is coming, and the combination therapy of metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) is a serious attack on prostate cancer
.

The discussion session was chaired by Prof.
Sheng Xinan from Peking University Cancer Hospital.
Prof.
Fan Yu from Peking University First Hospital, Prof.
Liu Hailong from Shanghai Xinhua Hospital, and Prof.
Chen Shouzhen from Qilu Hospital of Shandong University discussed "Experience in the diagnosis and treatment of intraductal carcinoma and neuroendocrine differentiated carcinoma of prostate cancer.
” and “appropriate timing of HRR detection in prostate cancer patients, sample selection and clinical significance of genetic testing” were discussed vigorously
.

Experts believe that due to the low incidence of the above specific subtypes, most centers have insufficient experience in diagnosis and treatment.
This guideline update should make more detailed recommendations for the above specific subtypes to meet the needs of more urological clinicians in the practice of diagnosis and treatment.
in demand
.

HRR mutation predicts a poor prognosis for patients, and genetic testing should be performed in the mCRPC stage.
When HRR mutation is positive, olaparib is recommended for treatment according to the PROfound study
.

In the next academic session, Professor Zeng Hao of West China Hospital of Sichuan University brought us the "Analysis of Important Research Progress of ASCO GU Prostate Cancer in 2022", and interpreted the four important oral reports announced in this ASCO GU meeting: Results of the PROPEL study, the MAGNITUDE study, the ARASENS study and the PRESIDE study
.

Among them, the PROpel study is the first randomized controlled phase III clinical study of the combination therapy in the whole first-line population of mCRPC
.

The study shows that the combination therapy of olaparib and abiraterone effectively improves the clinical outcomes of first-line mCRPC patients, extending the benefit of median imaging progression-free survival (rPFS) to more than 2 years, which is the first-line observation in mCRPC so far.
The longest rPFS benefit was achieved, the safety profile of the combination therapy was consistent with that of the two monotherapy, and the quality of life of the patients was not compromised, and the majority of patients were able to continue treatment until progression
.

The MAGNITUDE study, however, yielded negative results in the homologous recombination repair (HRR) unmutated population, worthy of further analysis
.

The release of the ARASENS study and the PRESIDE study also revealed that the era of "triple therapy" for mHSPC and mCRPC has truly come, and the future clinical practice will be rewritten
.

The discussion session was chaired by Prof.
Li Yonghong from Sun Yat-sen University Cancer Control Center.
Prof.
Guo Fang from Northern Theater General Hospital, Prof.
He Liru from Sun Yat-Sen University Cancer Control Center, and Prof.
Gu Weijie from Fudan University Affiliated Cancer Hospital discussed "PARP combined with NHA" and the "triple combination of mHSPC and mCRPC".
plan” to discuss
.

Experts said that the above major progress of ASCO GU are key studies that will significantly change clinical practice in the future, especially the PROpel study, MAGNITUDE and PRESIDE studies, which signify that mCRPC patients usher in a stronger combination therapy
.

Let us wait and see how it will be applied to the clinic in the future
.

At the end of the meeting, Professor Ye Dingwei, chairman of the CSCO Prostate Cancer Special Committee, gave a wonderful summary: "CSCO Prostate Cancer Diagnosis and Treatment Guidelines" was written by China's top experts in the field of prostate cancer with experience and wisdom, and will be organized next.
A series of meetings, together with domestic urology colleagues, will discuss the hot spots in the field of prostate cancer diagnosis and treatment, especially the academic hot spots that may change the guidelines
.

Thanks to all experts and scholars for their contributions, let us look forward to the 2022 edition of the "CSCO Guidelines for the Diagnosis and Treatment of Prostate Cancer"! Spring River Plumbing Duck Prophet, along with the successful convening of this guideline update kick-off meeting, the 2022 edition of the "CSCO Prostate Cancer Diagnosis and Treatment Guideline" update work has also officially kicked off! Let us look forward to the next "Guide Update Hotspot Analysis Meeting" to bring more exciting! Expert Profile Professor Ye Dingwei, Vice President of Fudan University Affiliated Cancer Hospital, Chief Expert of MDT in Urological Oncology Director of Shanghai Institute of Urological Oncology Director of Prostate Tumor Institute of Fudan University ) Chairman of the Chinese Society of Clinical Oncology (CSCO) Chairman of the Prostate Cancer Expert Committee Vice Chairman of the Renal Cancer Expert Committee of the Chinese Society of Oncology (CSCO) Vice Chairman of the Immunotherapy Expert Committee of the Chinese Society of Clinical Oncology (CSCO) Chairman of the Urinary Oncology Collaborative Group (UCOG) of the China Cancer Hospital Executive Director of the China Anti-Cancer Association and Executive Director of the Chinese Society of Clinical Oncology Director of the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GU) Prostate Cancer Group Leader NCCN Kidney Cancer Diagnosis and Treatment Guidelines Chinese Edition Deputy Leader NCCN Prostate Cancer, Kidney Cancer, Bladder Cancer Asian Diagnosis and Treatment Consensus Expert Committee Member of Advanced Prostate Cancer Asia Pacific Consensus Expert Committee Member etc.
* This article is only used to provide scientific information to medical professionals and does not represent the views of this platform